A practical reference on ACTH analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-25 and is reviewed periodically as new material appears.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide (ACTH fragment analog) | Not a steroid; does not belong to the melanocortin agonist drugs by marketing category |
| Molecular formula | C37H51N9O10S (commonly cited) | Reported values vary slightly with salt and counter-ion content |
| Appearance | White to off-white lyophilized powder | A single batch may appear as a loose cake or fluffy solid |
| Solubility | Freely soluble in water and aqueous buffer | Stock solutions are usually prepared in sterile water or saline |
| Typical storage | −20 °C or below, desiccated and protected from light | Seal opened vials promptly to limit moisture uptake |
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, with ultraviolet detection near 214 nanometers for the peptide backbone. Mass spectrometry, either electrospray or matrix-assisted laser desorption, confirms molecular mass and detects truncation or modification products. Amino acid analysis can verify composition. Because the sequence contains no strongly absorbing aromatic residue apart from phenylalanine, detection wavelengths are chosen carefully. Purity values above 95 percent are typical for research-grade material.
Quality documentation for research-grade peptide usually includes a certificate of analysis stating purity, identity, and residual counterion content. Batch-to-batch variation in purity and salt form is a recognized issue, and comparisons across suppliers require attention to the exact counterion, for example acetate versus trifluoroacetate. Sequence verification by tandem mass spectrometry provides stronger evidence than a single mass measurement. For any study reporting biological results, the analytical method and the measured purity should be stated explicitly. Independent verification of supplier claims is considered good practice.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
== Research == Much of the research conducted on demyelinating diseases is targeted towards discovering the mechanisms by which these disorders function in an attempt to develop therapies and treatments for individuals affected by these conditions. For example, proteomics has revealed several proteins which contribute to the pathophysiology of demyelinating diseases. For example, COX-2 has been implicated in oligodendrocyte death in animal models of demyelination. The presence of myelin debris has been correlated with damaging inflammation as well as poor regeneration, due to the presence of inhibitory myelin components. N-cadherin is expressed in regions of active remyelination and may play an important role in generating a local environment conducive to remyelination. N-cadherin agonists have been identified and observed to stimulate neurite growth and cell migration, key aspects of promoting axon growth and remyelination after injury or disease. Immunomodulatory drugs such as fingolimod have been shown to reduce immune-mediated damage to the CNS, preventing further damage in patients with MS. The drug targets the role of macrophages in disease progression. CNS-selective thyromimetics may become a viable strategy to protect myelin and promote remyelination in MS patients. It has been shown that intranasal administration of apotransferrin (aTf) can protect myelin and induce remyelination in mice. Finally, electrical stimulation which activates neural stem cells may provide a method by which regions of demyelination can be repaired.
== Early life and legal career == Kerry-Lynne Findlay was born in 1955 in Ladysmith, British Columbia, and lived in Nanaimo and Victoria; her brother Greg Findlay was a linebacker for the BC Lions Canadian Football League (CFL) team. She comes from a family with many former CFL players; Findlay's father Stephen Findlay played for the Hamilton Tigers in the 23rd Grey Cup. After graduating from Crofton House School in Vancouver, she attended the University of British Columbia, receiving a Bachelor of Arts degree in history and political science in 1975, and a law degree in 1978. She articled at Kowarsky and Company in Vancouver, then worked there as an associate for two years before briefly serving as in-house counsel for the Insurance Corporation of British Columbia. She established her own practice in 1981, then joined Connell Lightbody in 1987 before switching to Watson Goepel Maledy in 1996. During her legal career, Findlay has been active in both the national and B.C. provincial branch of the Canadian Bar Association. She held various positions in that organization including national and provincial chair of the Constitutional Law Section and member of the National Task Force on Canadian Court Reform, and she was acclaimed president of the B.C. Branch for the 1997–1998 term. Findlay was appointed Queen's Counsel in March 1999 by the Attorney General of British Columbia, and served a five-year term as a Member of the Canadian Human Rights Tribunal by appointment of the Federal Minister of Justice (2006–2011).
Initiatives since 2007 made English medium education mandatory nationwide. Following a 2012 attack on activist Malala Yousafzai by the Taliban, she became the youngest Nobel laureate for her education advocacy. Reforms in 2013 mandated Chinese language courses in Sindh, reflecting China's growing influence. As of 2018, Pakistan's literacy rate stands at 62.3%, with significant regional and gender disparities. Government initiatives, including computer literacy since 1995, aim to eradicate illiteracy, targeting 100% enrollment among primary school-age children and an ~86% literacy rate by 2015. Pakistan allocates 2.3% of its GDP to education, among the lowest in South Asia.
=== Tumours === Proteases are associated with cancer progression due to their ability to degrade extracellular matrices, which facilitates invasion and metastasis; these enzymes target a diversity of substrates and favour all steps of tumour production; some proteases have tumour-suppressive effects, associated with more than 30 different enzymes that belong to three distinct protease classes.
When the Atlantic slave trade began, many of the local slave systems began supplying captives for chattel slave markets outside Africa. Although the Atlantic slave trade was not the only slave trade from Africa, it was the largest in volume and intensity. As Elikia M'bokolo wrote in Le Monde diplomatique:
Sources: en.wikipedia.org
Open to people of Lithuanian descent; sponsors Lithuanian cultural programs, gives aid to widows, and orphans, relief for victims of natural disasters, and awards scholarships. On July 1, 2012, the insurance aspects of the organization passed to the Croatian Fraternal Union. A Special Convention convened on September 22, 2012, authorized the leadership to reconstitute the LAA as a not-for-profit cultural group. Lithuanian Catholic Alliance - Founded in 1886 as the Lithuanian Roman Catholic Alliance of America, adopted its current name in 1975. Headquarters in Wilkes-Barre, Pennsylvania. National convention meets triennially. There were 163 lodges in 1972 and 147 in 1977. 1965 membership was 7,000, which declined to 4,000 in 1979. In 1994 there were 3,069 members, despite membership being opened to non-Catholics. Sponsors Lithuanian cultural activities, cookbooks, films, and radio programs; also sponsors scholarships for members, supports Community Chest, blood donor clinics, Catholic youth programs, youth camps, and Catholic Social Services.
== Side effects == Common side effects associated with the use of flucloxacillin include: diarrhoea, nausea, rash, urticaria, pain and inflammation at injection site, superinfection (including candidiasis), allergy, and transient increases in liver enzymes and bilirubin. In fewer than 1 in 1,000 people, cholestatic jaundice (also referred to as cholestatic hepatitis) has been associated with flucloxacillin therapy. It may appear as pale stool with dark urine, and yellowish eyes and skin. The reaction may occur up to several weeks after treatment has stopped, and takes weeks to resolve. The estimated incidence is one in 15,000 exposures, and is more frequent in people over the age of 55, females, and those with a treatment duration of longer than two weeks. Flucloxacillin is contraindicated in those with a previous history of allergy to penicillins, cephalosporins, or carbapenems. It should also not be used in the eye, or administered to those with a history of cholestatic hepatitis associated with the use of dicloxacillin or flucloxacillin. It should be used with caution in the elderly, patients with renal impairment where a reduced dose is required, and those with hepatic impairment, due to the risk of cholestatic hepatitis. It should be taken on an empty stomach, as absorption is reduced when taken with food, though some studies suggest that this does not compromise flucloxacillin plasma concentrations in most circumstances.
== Approaches to Overcoming Size Limit == A major limiting factor in oligonucleotide synthesis is the progressive decline in yield as more nucleotides are included in the chain. Because each addition of a nucleotide is less than 100% efficient, the additive effect of coupling efficiency restricts a high yield synthesis to 13-200 nucleotides. The relationship between coupling efficiency and overall yield is described by the equation Y=CE^(n-1) where CE is the coupling efficiency, reported as a percentage, n representing the number of nucleotides, and n-1 representing the amount of coupling steps. As the number of coupling steps increases, the cumulative yield decreases exponentially. In response to yield constraints, various methodological improvements and alternative synthesis strategies have emerged to enhance coupling efficiency and extend oligonucleotide lengths:
== Protein == The human collagen alpha-1(XXI) chain is a 957-amino acid protein. As a FACIT collagen, it has a domain organization consisting of an N-terminal signal peptide followed by a single von Willebrand factor A (VWA) domain, a thrombospondin N-terminal (TSPN) domain, and a collagen triple-helical region that is interrupted by short non-collagenous segments. This interrupted triple-helical structure is the defining feature of the FACIT subfamily, whose members associate with the surfaces of major fibril-forming collagens rather than forming fibrils on their own. The mature protein is secreted into the extracellular space and localizes to the extracellular matrix.
Sources: en.wikipedia.org
It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.
It was developed in the Soviet Union during the early 1980s by groups at the Institute of Molecular Genetics in Moscow. Russian approval for intranasal use followed, and it has been marketed there since. Western laboratories encountered it mainly through translated literature and, later, through online research-chemical trade.
It holds a Russian registration as a prescription nasal product but has no approval from the European Medicines Agency or the United States Food and Drug Administration. Buyers outside Russia usually receive material sold strictly for laboratory research. That distinction matters because research-grade and pharmaceutical-grade products carry different documentation and testing expectations.
It consists mainly of animal experiments and small clinical reports, with much of the clinical material published in Russian-language journals. Large independent trials are scarce. Separating reliable effects from chance findings is consequently difficult.